Wyeth said Friday that U.S. regulators have again denied approval of the drug maker’s osteoporosis drug bazedoxifene requesting additional information on stroke and blood clot issues.
Wyeth Pharmaceuticals, Collegeville, announced today that it received its third “approvable” letter from the FDA for a drug being developed for the treatment of postmenopausal osteoporosis.
The Food and Drug Administration issued a third approvable letter for Wyeth Pharmaceuticals’ experimental drug bazedoxifene, which is being developed under the brand name Viviant to prevent postmenopausal osteoporosis. (WYE)